News & Updates
Filter by Specialty:

Neoadjuvant chemo plus durvalumab improves survival in NSCLC
30 Apr 2025
byStephen Padilla
The addition of durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel results in better survival rates among patients with resectable nonsmall cell lung cancer (NSCLC), according to a study presented at ELCC 2025.